Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study aims to unlock Cancer's immune secrets

NCT ID NCT03958240

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some cancers respond to immunotherapy and others do not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help researchers design better immunotherapies for several types of cancer.
What could go wrong
This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Jan 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with histologically documented local or metastatic solid malignant tumor (head and neck, ovarian, cervical, and other tumor types including, but not limited to glioblastoma, NSCLC and anal cancer) or patients with pre-invasive cervical high grade dysplasia (CIN II or III) 2. Age ≥ 18 years at the time of study entry 3. Patient followed within a standard of care procedure or clinical trial 4. ECOG Performance status 0-2 5. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol 6. Patient affiliated to a Social Health Insurance in France 7. Patient may participate to other clinical trials Exclusion Criteria: 1. Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or Hanta virus 2. Any condition contraindicated with blood sampling procedures required by the protocol (including Hemoglobin \< 8g/dl) 3. Patient pregnant, or breast-feeding 4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure 5. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm brain glioblastoma brain stem glioblastoma cervical cancer cervical intraepithelial neoplasia cervical intraepithelial neoplasia grade 2/3 glioblastoma glioma susceptibility 1 head and neck cancer Head and Neck Neoplasms neoplasm non-small cell lung carcinoma ovarian cancer Uterine Cervical Neoplasms uterine cervix carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal cancer Cervical cancer Cervical intraepithelial neoplasia 3 Glioblastoma multiforme of brain stem Head and neck cancer Non-small cell lung cancer Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital Larrey

    RECRUITING

    Toulouse, 31059, France

  • Hopital Rangueil

    RECRUITING

    Toulouse, 31059, France

  • Institut Universitaire du Cancer Toulouse - Oncopole

    RECRUITING

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.